Key result
Rare PLEC variants were not enriched in patients with arrhythmogenic right ventricular cardiomyopathy compared to controls (11% vs 18%, OR 0.55), indicating no major role for PLEC in this disorder.
Why the study?
Do rare PLEC variants increase susceptibility to arrhythmogenic right ventricular cardiomyopathy in patients compared to controls?
Case-Control (n=26,556)
Yes
Do rare PLEC variants increase susceptibility to arrhythmogenic right ventricular cardiomyopathy in patients compared to controls?
Rare PLEC variants are not enriched in ARVC patients compared to controls, suggesting that plectin variants do not play a major role in ARVC pathogenesis.
Answers are grounded in this paper and cite their sources.
Rare PLEC variants show no enrichment in ARVC; leaves open any minor or modifier role in select patients.
AIMS: Likely pathogenic/pathogenic variants in genes encoding desmosomal proteins play an important role in the pathophysiology of arrhythmogenic right ventricular cardiomyopathy (ARVC). However, for a substantial proportion of ARVC patients, the genetic substrate remains unknown. We hypothesized that plectin, a cytolinker protein encoded by the PLEC gene, could play a role in ARVC because it has been proposed to link the desmosomal protein desmoplakin to the cytoskeleton and therefore has a potential function in the desmosomal structure. METHODS: We screened PLEC in 359 ARVC patients and compared the frequency of rare coding PLEC variants (minor allele frequency [MAF] <0.001) between patients and controls. To assess the frequency of rare variants in the control population, we evaluated the rare coding variants (MAF <0.001) found in the European cohort of the Exome Aggregation Database. We further evaluated plectin localization by immunofluorescence in a subset of patients with and without a PLEC variant. RESULTS: Forty ARVC patients carried one or more rare PLEC variants (11%, 40/359). However, rare variants also seem to occur frequently in the control population (18%, 4754/26197 individuals). Nor did we find a difference in the prevalence of rare PLEC variants in ARVC patients with or without a desmosomal likely pathogenic/pathogenic variant (14% versus 8%, respectively). However, immunofluorescence analysis did show decreased plectin junctional localization in myocardial tissue from 5 ARVC patients with PLEC variants. CONCLUSIONS: Although PLEC has been hypothesized as a promising candidate gene for ARVC, our current study did not show an enrichment of rare PLEC variants in ARVC patients compared to controls and therefore does not support a major role for PLEC in this disorder. Although rare PLEC variants were associated with abnormal localization in cardiac tissue, the confluence of data does not support a role for plectin abnormalities in ARVC development.
No takes yet. Share an insight, caveat, or question.
Hoorntje et al. (2018) conducted a case-control in Arrhythmogenic right ventricular cardiomyopathy (n=26,556). Rare PLEC variants vs. ExAC European controls was evaluated on Proportion of individuals with one or more rare PLEC variants (OR 0.55, 95% CI 0.39-0.77, p=0.0002). Rare PLEC variants were not enriched in patients with arrhythmogenic right ventricular cardiomyopathy compared to controls (11% vs 18%, OR 0.55), indicating no major role for PLEC in this disorder.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: